How Eucalyptus Built US$450M Revenue Under Australia's Pharma Ad Ban
How Eucalyptus built $450M revenue by promoting telehealth services instead of drugs, circumventing Australia's strict TGA advertising restrictions. Hims acquisition signals global consolidation.
Australian health startup Eucalyptus was acquired by US-listed Hims & Hers Health on February 19, 2026, in a deal valued at up to US$1.15 billion, marking one of the largest telehealth consolidations in Asia-Pacific history.
Deal Structure and Financial Performance
The transaction includes an upfront payment of US$240 million, with deferred earnout payments contingent on performance through early 2029. Eucalyptus had reached an annual revenue run-rate exceeding US$450 million by 2025, more than double its prior-year revenue of A$120.9 million, despite never reaching profitability.
Mission Media
The company operates four consumer health brands: Juniper (women's weight and menopause care), Pilot (men's health), Kin (fertility), and Software (prescription skincare). At the time of acquisition, Eucalyptus served 775,000 customers.
Eucalyptus CEO Tim Doyle is expected to personally receive approximately US$160 million from the sale. Investors including Blackbird Ventures, Airtree Ventures, and Mary Meeker's BOND Capital all achieved exits. "Eucalyptus started seven years ago as a bet that generalist talent from Australia could build a globally competitive consumer healthcare business," Doyle said. "In many ways, this is the achievement of that aspiration."
How Eucalyptus Marketed in a Restricted Environment
Australia's Therapeutic Goods Administration (TGA) explicitly bans direct-to-consumer advertising of prescription medicines. Eucalyptus built its growth on a different approach: promoting the telehealth service and the health condition rather than the drug itself.
This strategy allowed the company to run a A$103 million marketing campaign featuring celebrity endorsements and Black Friday promotions for its Juniper weight-loss service, which prescribes GLP-1 drugs including Wegovy and Mounjaro. One anonymous former medical marketer described Juniper's approach as "arguably one of the best examples of circumnavigating the rules ever seen."
The company also hosted 62 promotional videos on a UK-based YouTube channel. Those videos featured Australian participants explicitly referencing GLP-1 drugs and demonstrating their use. Eucalyptus maintained only one video on its Australian channel. The company stated the UK content was intended solely for patients in that market.
The TGA fined competitor Midnight Health A$198,000 for directly promoting weight-loss drugs, illustrating the regulatory risk that Eucalyptus's service-focused model was designed to avoid.
Hims & Hers Cites International Regulatory Pressure
Hims & Hers CEO Andrew Dudum framed the acquisition as a deliberate move away from US regulatory volatility. The company has faced Novo Nordisk lawsuits and FDA scrutiny over compounded GLP-1 drugs in its home market.
"With Eucalyptus, we will not only enter new markets, we will expand our ability to serve customers globally, trusting local experts to be a key part of how we transform healthcare into a customer-first, personalized industry," Dudum said.
The acquisition adds operational presence in Australia, the UK, Germany, and Canada. Hims & Hers has identified Japan as its most significant long-term growth opportunity, citing the country's aging population and high healthcare spending.
Australian GLP-1 Market Provided Commercial Tailwind
Private spending on GLP-1 medications in Australia exceeded A$1 billion in the last reported year, with six million monthly injection kits sold between July 2024 and April 2025, according to a UNSW study. Eucalyptus's A$103 million marketing investment generated nearly A$250 million in revenue in a single financial year, an approximate 2:1 return in a strictly regulated market.
Eucalyptus also earned accreditation from the Australian Council on Healthcare Standards against EQuIP6 standards, providing institutional credibility alongside its consumer brand positioning.
Hims & Hers has stated the combined entity puts the company "on the path to becoming the leading global consumer health platform."
Want to reach thousands of marketing and comms professionals across Asia?
Get your brand in front of industry decision-makers.
Partner with Mission Media →
